10 Top Studies from The Liver Meeting 2023: At-a-Glance
Simplified risk stratification tools for NAFLD, effects of statins on hepatic disease, trends in OHE, and patient perspectives are samples of the noteworthy research areas.
Updated Guidelines for Atrial Fibrillation from ACC/AHA Focus on Aggressive Prevention and Control and a Continuum of Care
The revised guidance classifies AF into 4 stages, emphasizes prevention and aggressive rhythm control, and upgrades recommendations for catheter ablation and LAA occlusion.
Obesity Advocacy Groups Say Exclusion of People with Obesity from Drug Research Must Stop
The 5 leading advocacy groups said the safety of people with obesity is at risk and called on the FDA to change clinical trial inclusion requirements and expedite labeling changes.
Treat the Neuropathic Pain—and the Rest of the Person, Too: PM&R Physician Saloni Sharma, MD
Physiatrist Saloni Sharma, MD, stresses the essential role of coordinated, multidisciplinary care for a person with neuropathic pain—and any person with limited function.
CV Risk Factors Increasing Among Middle-Aged US Adults, Socioeconomic Inequities Persist: New Findings
Cardiovascular mortality has been increasing among middle-aged US adult since 2011; a new study looked at changes in CV risk factors by income level over the past 20 years.
Dupilumab sBLA Submission for COPD Accelerated Based on Second Positive Phase 3 Trial Findings
Dupilumab reduced COPD exacerbations by more than one-third in the phase 3 NOTUS trial, matching outcomes from the earlier BOREAS study this year.
How to Build Assessment for Cardiovascular-Kidney-Metabolic Syndrome into Primary CVD Prevention
Chiadi Ndumele, MD, PhD, MHS, offers 3 thoughts for primary care on incorporating CKM syndrome screening into daily clinical practice.
Physiatry's Focus on the Whole Person and Collaborative Care is an Ideal Rx for Neuropathic Pain
According to physical medicine and rehabilitation physician Saloni Sharma, MD, treatment for neuropathic pain draws on PM&R's many strengths.
Phase 3 Trial of Factor XIa Inhibitor Asundexian Halted for Lack of Efficacy
The novel oral anticoagulant is one in a class of agents for prevention of AF-related stroke that shows promise to reduce bleeding risk.
Primary Care is the Quarterback in Effective Care for Cardiovascular-Kidney-Metabolic Syndrome
"Primary care physicians... really are like the quarterbacks" for initiating multidisciplinary care for CKM syndrome, says Dr Chiadi Ndumele.
New CVD Risk Equations are Sex-Specific, Exclude Race, Include eGFR, and Predict Heart Failure
Absolute risk assessment for CVD remains the corner-stone of clinical primary prevention efforts. The new AHA prediction models expand that foundation.
We Need to Shift Social Determinants of Health into Our Clinical Workflow, says Chiadi Ndumele, MD, PhD, MHS
Managing cardiovascular-kidney-metabolic syndrome on a population-wide basis requires that social determinants of health be treated like any other risk factor, according to Ndumele.
AHA Proposes Redefined CVD Risk Calculation in Cardiovascular Kidney Metabolic Syndrome
Dr Chiadi Ndumele explains the need for the more comprehensive and also nuanced qualitative approach to estimating long-term CVD risk.
The 4 Stages of CKM Syndrome Offer Opportunities to Stop Progression, Promote Regression
Chiadi Ndumele, MD, PhD, MHS, of Johns Hopkins University, details features of the new 4-stage construct that guides CKM diagnosis and promotes early disease intervention.
Common Menstrual Disorders Increase Risk for Future CVD in Young Women
Polycystic ovary syndrome and dysmenorrhea were both identified as reproductive disorders that could help stratify CVD risk in women.
"CKM Syndrome" Defines a Very Wide Target and Medicine is Ready, Says Chiadi Ndumele, MD, PhD, MHS
Ndumele chairs the American Heart Association committee that characterized the syndrome and wrote the statement of evidence for its assessment and management.
Speech May be a Promising Biomarker for MHE, OHE, According to New Research
TLM 2023: Speech analyzed from a smartphone app recording identified MHE and predicted OHE with results comparable to those from validated assessments.
How to Change the Course of Chronic Liver Disease in the US: Create a Groundswell Movement
TLM 2023: Reduce disease stigma and treatment inequality, build awareness for early diagnosis across specialties, support clinicians with accessible tools, and that's a start.
NASH Diagnosis: Patients Overwhelmed But Motivated to Adhere to Guidance and Want More Help, Survey Finds
More education that is clear and from reliable sources is needed for patients with a NASH diagnosis and their caregivers throughout the duration of the disease.
Cloud-Based "Liver Toolkit" Identifies Primary Care Patients at High Risk for Fibrosis, Requiring Referral
One in 5 patients identified as at risk for advanced chronic liver disease had advanced fibrosis and PCP was prompted to refer to hepatology.
New NAFLD Familial Risk Score Outperforms FIB-4 for Predicting Advanced Fibrosis in First-Degree Relatives
TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.
Novel Algorithm, FAST-3, Shows Promise as Noninvasive Classifier for Advanced Fibrosis in MASLD
The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.
Hepatic Steatosis is a Risk Factor for MACE, Even Among Individuals at Low 10-Year ASCVD Risk
TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.
Rifaximin Significantly Reduced Recurrent OHE and Associated Health Care Utilization
TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.
Statin Protection Against Cirrhosis in Adults with NAFLD More Pronounced with Age
TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.
Chronic Liver Disease Prevalence May Triple by Decade's End, New Report Projects
Driven largely by the widespread increase in diabetes and obesity, the rise in hepatic disease disparately affects minority populations and is outpacing available medical care.
Tirzepatide Approved by FDA for Chronic Weight Management in Adults
The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.
It's High Time to Retire NAFLD: Multinational Liver Societies Explain
NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.
NAFLD is Now MASLD: The New Nomenclature, At-a-Glance
The shift in naming for diseases historically known as nonalcoholic fatty liver disease will be top of mind at The Liver Meeting 2023. Get a quick look at why.
The Liver Meeting 2023: AASLD Offers "Journey Maps" to Focused Areas of Interest
We took The Liver Meeting's 11 journey maps to educational sessions and focused on 4 that will be of interest to primary care.
